Mayne Pharma Group Ltd

Mayne Pharma Group Ltd has a market capitalization of 201,489,650.96 AUD, with a current market price of 2.48 AUD per share. The company has 81,245,827 basic and diluted shares outstanding, indicating no immediate dilution pressure from share issuance. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's profitability and returns are not directly quantifiable due to the lack of detailed financial metrics such as ROIC, EBITDA margins, or net profit margins in the valuation snapshot. Analysts have assigned a mean price target of 6.10 AUD, with a median and high target also at 6.10 AUD, suggesting a consensus on potential upside. The mean recommendation score is 2.00, indicating a "Buy" rating, with one analyst issuing a "Buy" recommendation and none issuing a "Strong Buy". Mayne Pharma Group Ltd's revenue concentration and geographic exposure are not disclosed in the available data. The company operates in the pharmaceuticals industry, which is typically characterized by high R&D intensity and regulatory scrutiny, but no specific segments or geographic breakdowns are provided. The company's growth trajectory is not quantified in the available data. Analysts have not provided forward-looking revenue growth estimates, and the outlook for the current and next fiscal years is not specified. However, the consensus price target of 6.10 AUD implies a potential upside of over 146% from the current market price. Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and the absence of going-concern language in source documents. The company is also exposed to the typical risks of the pharmaceutical industry, such as regulatory changes, patent expirations, and R&D uncertainties, though no specific risk events are disclosed in the available data. Recent events and filings are not detailed in the available data. The company's risk assessment does not include any specific recent regulatory or operational events, and no transcripts or filings are cited in the source documents.